botox 200 allergan units inj. opl. (pdr.) i.m./i.derm. flac.
abbvie sa-nv - clostridium botulinum toxine type a - poeder voor oplossing voor injectie - clostridium botulinum toxine type a 200 e - botulinum toxin
botox 50 allergan units inj. opl. (pdr.) i.m./s.c. flac.
abbvie sa-nv - clostridium botulinum toxine type a - poeder voor oplossing voor injectie - clostridium botulinum toxine type a 50 e - botulinum toxin
betagan liquifilm 0,5%, oogdruppels, oplossing
allergan pharmaceuticals ireland castlebar road westport, co. mayo (ierland) - levobunololhydrochloride samenstelling overeenkomend met ; levobunolol - oogdruppels, oplossing - benzalkoniumchloride ; dinatriumedetaat 2-water ; dinatriumwaterstoffosfaat 7-water (e 339) ; kaliumdiwaterstoffosfaat 0-water (e 340) ; natriumchloride ; natriumhydroxide (e 524) ; natriummetabisulfiet (e 223) ; polyvinylalcohol (e1203) ; water, gezuiverd ; zoutzuur (e 507), - levobunolol
betagan 0,50 % oogdruppels opl. druppelfl.
allergan pharmaceuticals ireland ltd. - levobunololhydrochloride 5 mg/ml - oogdruppels, oplossing - 0,50 % - levobunololhydrochloride 5 mg/ml - betaxolol
phelinun
adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastische middelen - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - multiple myeloma - antineoplastische middelen - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
melphalan tillomed 50 mg inj./inf. sol. (pwdr. + solv.) i.v./i.arter. vial
melphalan tillomed 50 mg sol. inj./perf. (pdr. + solv.) i.v./i.artér. flac.
melphalan tillomed 50 mg pulver und lösungsmittel zur herstellung einer injektions- bzw. infusionslösung
norditropin flexpro 10 mg/1,5ml, oplossing voor injectie in een voorgevulde pen
novo nordisk b.v. flemingweg 8 2408 av alphen aan den rijn - somatropine (rdna) 6,7 mg/ml - oplossing voor injectie - fenol ; histidine, (l-) ; mannitol (d-) (e 421) ; natriumhydroxide (e 524) ; poloxameer 188 ; water voor injectie ; zoutzuur (e 507), - somatropin